Loading...
Intas Pharmaceuticals Limited — Repaglinide Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #4 for Repaglinide · $343.0K export value · DGFT Verified
Intas Pharmaceuticals Limited is the #4 Indian exporter of Repaglinide with $343.0K in export value and 173 verified shipments. Intas Pharmaceuticals Limited holds a 5.0% market share in Repaglinide exports across 6 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| CROATIA | $199.5K | 20 | 56.2% |
| NETHERLANDS | $90.4K | 57 | 25.5% |
| POLAND | $43.8K | 16 | 12.4% |
| ITALY | $12.8K | 82 | 3.6% |
| AUSTRIA | $5.8K | 12 | 1.6% |
| UNITED KINGDOM | $2.4K | 1 | 0.7% |
Intas Pharmaceuticals Limited exports Repaglinide to 6 countries. The largest destination is CROATIA accounting for 56.2% of Intas Pharmaceuticals Limited's Repaglinide shipments, followed by NETHERLANDS (25.5%) and POLAND (12.4%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NOVATIN LIMITED | CROATIA | $88.8K | 6 |
| BROCACEF NL : HUB | NETHERLANDS | $53.6K | 33 |
| NOVATIN LIMITED CONSIGNEMENT STOCK | CROATIA | $50.1K | 2 |
| TO THE ORDER., | CROATIA | $37.0K | 4 |
| BROCACEF NL HUB BROCACEF HEALTHCAR | NETHERLANDS | $26.2K | 10 |
| NOVATIN LTD CONSIGNEMENT STOCK | CROATIA | $23.6K | 8 |
India exported $6.9M worth of Repaglinide through 819 shipments from 41 suppliers to 36 countries, serving 112 buyers globally. Intas Pharmaceuticals Limited contributes $343.0K to this total, accounting for 5.0% of India's Repaglinide exports. Intas Pharmaceuticals Limited ships Repaglinide to 6 countries through 23 buyers.
Intas Pharmaceuticals Limited's average Repaglinide shipment value is $2.0K per consignment, based on 173 shipments totaling $343.0K. The largest destination is CROATIA (56.2% of Intas Pharmaceuticals Limited's Repaglinide exports).
Intas Pharmaceuticals Limited ranks #4 among 41 Indian Repaglinide exporters with a 5.0% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($3.6M), AUROBINDO PHARMA LIMITED ($1.8M), USV PRIVATE LIMITED ($883.7K). Intas Pharmaceuticals Limited processed 173 shipments to 6 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PH.DRU.& MED.: VATINID 2MG TABLETS REPAGLINIDE TABLETS 2MG EACH TABLET CONTAINS: REPAGLINIDE 2MG [9X10T PER PACK] | $50.1K | 2 |
| PHARMA DRUG&MED: VATINID 2MG REPAGLINIDE9X10T(NOVA-CZ)EACH UNCOATED TABLET CONTAINS: REPAGLINIDE 2 MG EXCIPIENTS: Q.S. | $50.0K | 1 |
| PH.DRU.& MED.: VATINID 1MG TABLETS REPAGLINIDE TABLETS 1MG EACH TABLET CONTAINS: REPAGLINIDE 1MG [9X10T PER PACK] | $28.3K | 2 |
| PHARMA.DRUGS & MEDICINE VATINID 1MG REPAGLINIDE 9X10T(NOVA-CZ)EACH UNCOATED TABLET CONTS:REPAGLINIDE 1MG EXCIPIENTS:Q.S. | $20.3K | 3 |
| PHARM DRUG&MED:REPAGLINIDE ACCORD 0.5 MGEACH UNCOATED TABLET CONTAINS :REPAGLINIDE PH.EUR............0.5 MG | $19.9K | 2 |
| PH.DRU.& MED.: VATINID 2MG TABLETS (REPAGLINIDE TABLETS 2MG EACH TABLET CONT. REPAGLINIDE 2MG) [11697 PACK X9X10T] | $18.7K | 1 |
| PH.DRU.& MED.: VATINID 2MG TABLETS (REPAGLINIDE TABLETS 2MG EACH TABLET CONT. REPAGLINIDE 2MG) [11363 PACK X9X10T] | $18.2K |
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | AUROBINDO PHARMA LIMITED | $1.8M | 136 | 6 | $13.0K |
| 3 | USV PRIVATE LIMITED | $883.7K | 46 | 4 | $19.2K |
| 4 | INTAS PHARMACEUTICALS LIMITED ★ | $343.0K | 173 | 6 | $2.0K |
| 5 | MACLEODS PHARMACEUTICALS LTD | $267.7K | 17 | 1 |
| Port | Shipments | % Share |
|---|---|---|
| HYDERABAD ICD (INSNF6) | 110 | 13.4% |
| HYDERABAD ICD | 95 | 11.6% |
| SAHAR AIR | 81 | 9.9% |
| HYDERABAD AIR | 54 | 6.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 51 | 6.2% |
| DELHI AIR | 48 | 5.9% |
| ICD SANATHNAGAR, HYD | 48 | 5.9% |
| DELHI AIR CARGO ACC (INDEL4) | 46 | 5.6% |
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Repaglinide, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Repaglinide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Repaglinide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
| ACCORD HEALTHCARE POLSKA SP ZOO MAGAZYN IMPORTERA UL LUTOMIERSKA |
| POLAND |
| $23.6K |
| 3 |
| ACCORD HEALTHCARE ITALIA SRL | ITALY | $11.3K | 6 |
| ALLOGA FRANCE | NETHERLANDS | $10.0K | 12 |
| ACCORD HEALTHCARE POLSKA SP. Z.O.O. | POLAND | $8.5K | 6 |
Intas Pharmaceuticals Limited supplies Repaglinide to 23 buyers globally. The largest buyer is NOVATIN LIMITED (CROATIA), followed by BROCACEF NL : HUB (NETHERLANDS) and NOVATIN LIMITED CONSIGNEMENT STOCK (CROATIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| 1 |
| PHARM DRUG&MED:REPAGLINIDE 2MG 9X10TACORD-CZEACH UNCOATED TABLET CONTAINS :REPAGLINIDE PH.EUR............2 MG | $17.4K | 2 |
| PHARMA DRUGS & MEDI Repaglinide Accord 1 | $17.0K | 6 |
| PHARMA DRUGS & MEDI Repaglinide Accord 2 | $10.6K | 7 |
Intas Pharmaceuticals Limited exports 93 distinct Repaglinide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PH.DRU.& MED.: VATINID 2MG TABLETS REPAGLINIDE TABLETS 2MG E with 2 shipments worth $50.1K.
| $15.7K |
| 6 | GLOBAL PHARMA HEALTHCARE PRIVATE LIMITED | $48.3K | 15 | 2 | $3.2K |
Intas Pharmaceuticals Limited ranks #4 among 41 Indian Repaglinide exporters. Average shipment value of $2.0K compared to the market average of $168.2K. The closest competitors by value are AUROBINDO PHARMA LIMITED and USV PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 36+ countries, 112+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Repaglinide. For current shipment-level data, contact TransData Nexus.